Morgan's Scott Power highlights nine ASX healthcare companies from the 2025 Bioshares Biotech Summit with catalysts over next ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Bell Potter notes that Neuren has released an update on Acadia's sales and its expected royalties. It said: ...

NasdaqGS:ACAD 1 Year Share Price vs Fair Value Explore ACADIA Pharmaceuticals's Fair Values from the Community ...

Second Quarter 2025 Results Key Financial Results Revenue: US$264.6m (up ...

Biotech group Neuren Pharmaceuticals has reported a 14% uptick in quarterly US sales of its Retts syndrome treatment Daybue.

Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

Shares little changed from Wednesday’s record; ASX hammered on monopoly chatter, costs hit; Domain to exit sharemarket after ...

Shares little changed from Wednesday’s record; ASX hammered on monopoly chatter, costs hit; Domain to exit sharemarket after ...

Despite firming US sales of its Rett syndrome treatment Daybue, Neuren Pharmaceuticals (ASX:NEU) says two-thirds of eligible ...

Acadia Pharma (ACAD) is scheduled to announce Q2 earnings results on Wednesday, August 6th, after market close.